Clinical effect of vitamin&nbsp;D supplementation on patients with pulmonary tuberculosis and its influence on the expression of immune cells and inflammatory factors

Cheng,Chunxu; Pan,Weina; Li,Xiang; Qu,Hongyan

doi:10.3892/etm.2020.8957

Clinical effect of vitamin D supplementation on patients with pulmonary tuberculosis and its influence on the expression of immune cells and inflammatory factors

Authors:
- Chunxu Cheng
- Weina Pan
- Xiang Li
- Hongyan Qu
View Affiliations

Affiliations: Department of Infectious Diseases, Changchun Hospital for Infectious Diseases, Changchun, Jilin 130031, P.R. China, Department of Radiology, The Third People's Hospital of Gongzhuling City, Siping, Jilin 136105, P.R. China, Department of Drug‑Resistant Tuberculosis, Changchun Hospital for Infectious Diseases, Changchun, Jilin 130031, P.R. China
Published online on: June 29, 2020 https://doi.org/10.3892/etm.2020.8957
Pages: 2236-2244
Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tuberculosis is highly infectious and has a high incidence worldwide. Therefore, effective treatment is essential for the disease. The immune function and inflammatory factors can reflect the therapeutic effect of pulmonary tuberculosis to some extent. Thus, the aim of the present study was to investigate the clinical effect of vitamin D supplementation on pulmonary tuberculosis patients and its influence on the expression of immune cells and inflammatory factors in patients. A total of 256 patients with pulmonary tuberculosis who were admitted to our hospital were collected as research participants; 120 patients who were treated with conventional antituberculosis drugs were taken as a control group (CG) and 136 patients who were treated with vitamin D‑assisted antituberculosis drugs were taken as the research group (RG). The levels of inflammatory factors (IL‑6, MMP‑9, IL‑4, TNF‑α) and T lymphocyte subgroup of patients were measured in both groups before and after treatment. The efficacy was compared in both groups. The disappearance time of wheezing and cough in RG was shorter than that in CG (P<0.001). There was no difference in X‑ray chest plain film, sputum examination results and efficacy of patients in both groups (P>0.05). After treatment, CD3+, CD4+, CD4+/CD8+ were upregulated in both groups (P<0.05), while CD3+, CD4+, CD4+/CD8+ in RG were higher than those in CG (P<0.05). After treatment, inflammatory factors in both groups improved compared with those before treatment. Serum inflammatory factors in RG were significantly lower than those in CG (P<0.05). After treatment, surfactant protein in the two groups was lower than that before treatment, while that in RG was significantly lower than that in CG (P<0.05). After treatment, soluble selectins in both groups improved significantly. The level of soluble selectins in RG was slightly lower than that in CG. The incidence of adverse reactions in RG was lower than that in CG. The life quality scores of patients in RG were slightly higher than those in CG (P<0.05). In conclusion, vitamin D‑assisted antituberculosis drugs can effectively improve the immune function and expression level of inflammatory factors in pulmonary tuberculosis patients and reduce adverse reactions.

View Figures

View References

1	Guo Z, Xiao D, Wang X, Wang Y and Yan T: Epidemiological characteristics of pulmonary tuberculosis in mainland China from 2004 to 2015: A model-based analysis. BMC Public Health. 19(219)2019.PubMed/NCBI View Article : Google Scholar
2	Xu Y, Wu J, Liao S and Sun Z: Treating tuberculosis with high doses of anti-TB drugs: Mechanisms and outcomes. Ann Clin Microbiol Antimicrob. 16(67)2017.PubMed/NCBI View Article : Google Scholar
3	Carvalho AC, Cardoso CA, Martire TM, Migliori GB and Sant'Anna CC: Epidemiological aspects, clinical manifestations, and prevention of pediatric tuberculosis from the perspective of the end TB strategy. J Bras Pneumol. 44:134–144. 2018.PubMed/NCBI View Article : Google Scholar : (In Portuguese, English).
4	Rao VG, Bhat J, Yadav R, Muniyandi M, Bhondeley MK and Wares DF: Yield of pulmonary tuberculosis cases by symptoms: Findings from a community survey in Madhya Pradesh, central India. Indian J Tuberc. 62:121–123. 2015.PubMed/NCBI View Article : Google Scholar
5	Shen X, Zhang J, Tang P, Song H, Liu X, Huang Z, Zhang X, Wang X and Wu M: Expression and clinical significance of B and T lymphocyte attenuator on CD4⁺ and CD8⁺ T cells from patients with pulmonary tuberculosis. Indian J Pathol Microbiol. 62:232–238. 2019.PubMed/NCBI View Article : Google Scholar
6	Peng X, Luo T, Zhai X, Zhang C, Suo J, Ma P, Wang C and Bao L: PPE11 of Mycobacterium tuberculosis can alter host inflammatory response and trigger cell death. Microb Pathog. 126:45–55. 2019.PubMed/NCBI View Article : Google Scholar
7	Rekha RS, Mily A, Sultana T, Haq A, Ahmed S, Mostafa Kamal SM, van Schadewijk A, Hiemstra PS, Gudmundsson GH, Agerberth B and Raqib R: Immune responses in the treatment of drug-sensitive pulmonary tuberculosis with phenylbutyrate and vitamin D₃ as host directed therapy. BMC Infect Dis. 18(303)2018.PubMed/NCBI View Article : Google Scholar
8	Tomio J, Yamana H, Matsui H, Yamashita H, Yoshiyama T and Yasunaga H: Tuberculosis screening prior to anti-tumor necrosis factor therapy among patients with immune-mediated inflammatory diseases in Japan: A longitudinal study using a large-scale health insurance claims database. Int J Rheum Dis. 20:1674–1683. 2017.PubMed/NCBI View Article : Google Scholar
9	Tornheim JA and Dooley KE: The global landscape of tuberculosis therapeutics. Annu Rev Med. 70:105–120. 2019.PubMed/NCBI View Article : Google Scholar
10	Khameneh B, Fazly Bazzaz BS, Amani A, Rostami J and Vahdati-Mashhadian N: Combination of anti-tuberculosis drugs with vitamin C or NAC against different Staphylococcus aureus and Mycobacterium tuberculosis strains. Microb Pathog. 93:83–87. 2016.PubMed/NCBI View Article : Google Scholar
11	Zittermann A: Vitamin D in preventive medicine: Are we ignoring the evidence? Br J Nutr. 89:552–572. 2003.PubMed/NCBI View Article : Google Scholar
12	Syal K, Chakraborty S, Bhattacharyya R and Banerjee D: Combined inhalation and oral supplementation of Vitamin A and Vitamin D: A possible prevention and therapy for tuberculosis. Med Hypotheses. 84:199–203. 2015.PubMed/NCBI View Article : Google Scholar
13	Huang SJ, Wang XH, Liu ZD, Cao WL, Han Y, Ma AG and Xu SF: Vitamin D deficiency and the risk of tuberculosis: A meta-analysis. Drug Des Devel Ther. 11:91–102. 2016.PubMed/NCBI View Article : Google Scholar
14	Li CT, Chu KH, Reiher B, Kienene T and Chien LY: Evaluation of health-related quality of life in patients with tuberculosis who completed treatment in Kiribati. J Int Med Res. 45:610–620. 2017.PubMed/NCBI View Article : Google Scholar
15	Ossalé Abacka KB, Koné A, Akoli Ekoya O, Bopaka RG, Lankoandé Siri H and Horo K: Extrapulmonary tuberculosis versus pulmonary tuberculosis: Epidemiological, diagnosis and evolutive aspects. Rev Pneumol Clin. 74:452–457. 2018.PubMed/NCBI View Article : Google Scholar : (In French).
16	Maitra A, Kamil TK, Shaik M, Danquah CA, Chrzastek A and Bhakta S: Early diagnosis and effective treatment regimens are the keys to tackle antimicrobial resistance in tuberculosis (TB): A report from Euroscicon's international TB Summit 2016. Virulence. 8:1005–1024. 2017.PubMed/NCBI View Article : Google Scholar
17	Churchyard G, Kim P, Shah NS, Rustomjee R, Gandhi N, Mathema B, Dowdy D, Kasmar A and Cardenas V: What we know about tuberculosis transmission: An overview. J Infect Dis. 216 (suppl 6):S629–S635. 2017.PubMed/NCBI View Article : Google Scholar
18	Reynolds IR and Chan ED: An update on the trends and treatment in multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 193:A5533. 2016.
19	An J, Bai X, Gao M, Chu N, Huang H, Xu H, Zhang X, Li B, Huang C, Cai H, et al: Antituberculosis drug prescribing for inpatients in a national tuberculosis hospital in China, 2011-2015. J Glob Antimicrob Resist. 14:17–22. 2018.PubMed/NCBI View Article : Google Scholar
20	Gegia M, Winters N, Benedetti A, van Soolingen D and Menzies D: Treatment of isoniazid-resistant tuberculosis with first-line drugs: A systematic review and meta-analysis. Lancet Infect Dis. 17:223–234. 2017.PubMed/NCBI View Article : Google Scholar
21	Hu Y, Wu X, Luo J, Fu Y, Zhao L, Ma Y, Li Y, Liang Q, Shang Y and Huang H: Detection of pyrazinamide resistance of Mycobacterium tuberculosis using nicotinamide as a surrogate. Clin Microbiol Infect. 23:835–838. 2017.PubMed/NCBI View Article : Google Scholar
22	Alessandra C Pinheiro and Marcus V N de Souza. The relevance of new drug combinations for modern tuberculosis treatment-a patent perspective. Recent Pat Antiinfect Drug Discov. 8:130–138. 2013.PubMed/NCBI View Article : Google Scholar
23	Li C, Liu L and Tao Y: Diagnosis and treatment of congenital tuberculosis: A systematic review of 92 cases. Orphanet J Rare Dis. 14(131)2019.PubMed/NCBI View Article : Google Scholar
24	Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, et al: Official American Thoracic Society/Infectious Diseases Society of America/Centers for disease control and prevention clinical practice guidelines: Diagnosis of tuberculosis in adults and children. Clin Infect Dis. 64:–e1. –e33. 2017.PubMed/NCBI View Article : Google Scholar
25	Haris R, Irbaz R, Tanvir A, Maaz B and Abul M: Vitamin D as a supplementary agent in the treatment of pulmonary tuberculosis: A systematic review and meta-analysis of randomized controlled trials. Eur Respir J. 42(4623)2013.
26	Li C, Zhou HC, Nie YL, Zhao BY and Wu CC: Effects of lipopolysaccharide on T lymphocyte cell subsets and cytokine secretion in mesenteric lymph nodes of mice: Histological and molecular study. Environ Toxicol Pharmacol. 71(103214)2019.PubMed/NCBI View Article : Google Scholar
27	Pérez-Antón E, Egui A, Thomas MC, Puerta CJ, González JM, Cuéllar A, Segovia M and López MC: Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4⁺CD8⁺ T cells in chronic Chagas disease patients. PLoS Negl Trop Dis. 12(e0006480)2018.PubMed/NCBI View Article : Google Scholar
28	Muller L, Mitsuhashi M, Simms P, Gooding WE and Whiteside TL: Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. Sci Rep. 6(20254)2016.PubMed/NCBI View Article : Google Scholar
29	Jiménez-Sousa MÁ, Martínez I, Medrano LM, Fernández-Rodríguez A and Resino S: Vitamin D in human immunodeficiency virus infection: Influence on immunity and disease. Front Immunol. 9(458)2018.PubMed/NCBI View Article : Google Scholar
30	Naik SP, Mahesh PA, Jayaraj BS, Madhunapantula SV, Jahromi SR and Yadav MK: Evaluation of inflammatory markers interleukin-6 (IL-6) and matrix metalloproteinase-9 (MMP-9) in asthma. J Asthma. 54:584–593. 2017.PubMed/NCBI View Article : Google Scholar
31	Acharya AB, Thakur S, Muddapur MV and Kulkarni RD: Tumor necrosis factor-α, interleukin-4 and -6 in the serum of health, chronic periodontitis, and type 2 diabetes mellitus. J Indian Soc Periodontol. 20:509–513. 2016.PubMed/NCBI View Article : Google Scholar
32	Selvaraj P, Harishankar M and Afsal K: Vitamin D: Immuno-modulation and tuberculosis treatment. Can J Physiol Pharmacol. 93:377–384. 2015.PubMed/NCBI View Article : Google Scholar
33	Güzel A, Karadağ A, Okuyucu A, Alaçam H and Küçük Y: The evaluation of serum surfactant protein D (SP-D) levels as a biomarker of lung injury in tuberculosis and different lung diseases. Clin Lab. 60:1091–1098. 2014.PubMed/NCBI View Article : Google Scholar
34	Enomoto Y, Hagiwara E, Komatsu S, Nishihira R, Baba T and Ogura T: Comparison of biomarkers of pulmonary tuberculosis activity-serum surfactant proteins A and D, KL-6, C-reactive protein, and erythrocyte sedimentation rate. Kekkaku. 89:637–642. 2014.PubMed/NCBI(In Japanese).
35	Serré J, Mathyssen C, Ajime TT, Korf H, Maes K, Heulens N, Gysemans C, Mathieu C, Vanaudenaerde B, Janssens W and Gayan-Ramirez G: Data on inflammatory cytokines and pathways involved in clearance of nontypeable Haemophilus influenzae from the lungs during cigarette smoking and vitamin D deficiency. Data Brief. 22:703–708. 2018.PubMed/NCBI View Article : Google Scholar
36	Mukae H, Ashitani J, Tokojima M, Ihi T, Kohno S and Matsukura S: Elevated levels of circulating adhesion molecules in patients with active pulmonary tuberculosis. Respirology. 8:326–331. 2003.PubMed/NCBI View Article : Google Scholar
37	Nowak JK, Wojsyk-Banaszak I, Mądry E, Wykrętowicz A, Krzyżanowska P, Drzymała-Czyż S, Nowicka A, Pogorzelski A, Sapiejka E, Skorupa W, et al: Increased soluble VCAM-1 and normal P-selectin in cystic fibrosis: A cross-sectional study. Lung. 195:445–453. 2017.PubMed/NCBI View Article : Google Scholar
38	Xia J, Shi L, Zhao L and Xu F: Impact of vitamin D supplementation on the outcome of tuberculosis treatment: A systematic review and meta-analysis of randomized controlled trials. Chin Med J (Engl). 127:3127–3134. 2014.PubMed/NCBI
39	Bai YJ and Dai RJ: Serum levels of vitamin A and 25-hydroxyvitamin D3 (25OHD₃) as reflectors of pulmonary function and quality of life (QOL) in children with sTable asthma: A case-control study. Medicine (Baltimore). 97(e9830)2018.PubMed/NCBI View Article : Google Scholar
40	Alavi Foumani A, Mehrdad M, Jafarinezhad A, Nokani K and Jafari A: Impact of vitamin D on spirometry findings and quality of life in patients with chronic obstructive pulmonary disease: A randomized, double-blinded, placebo-controlled clinical trial. Int J Chron Obstruct Pulmon Dis. 14:1495–1501. 2019.PubMed/NCBI View Article : Google Scholar